(Date:11/9/2009)...ire-USNewswire/ -- New Mayo Clinic research has fo...dramatically reduces patient hospital stay and rec...s week at the North Central Section of the America..., (Logo: http://www.newscom.com/cgi-bin/prnh/20...l audio and video resources, including excerpts fr...
(Date:11/9/2009)...wire/ -- At a time when the 250,000+ eligible Medi...d about finding affordable health insurance, they ..., The Today,s Options® Preferred Provider ...s a cost-effective and comprehensive alternative t... People with Medicare can choose to sign up for t...
(Date:11/9/2009)... our current campaign finance system ,, WASHIN... Congress who noted "no" on health care reform leg...llion more in campaign donations from health insur...e legislation to overhaul of the nation,s health c...alition of campaign reform groups. ,, "The heal...
(Date:11/9/2009)... , , WHAT: All PETCO stores nationwide will...facilitated by specially trained in-store nutritio...t 2 p.m. During the 30-minute, works...needs of, their dogs and cats, have a...ood pet nutrition, receive an assessment of their ...
(Date:11/9/2009)... and the University of Florida Proton Therapy Inst...n therapy for St. Jude patients. The announcement ...o evaluate the use of proton therapy for rare brai..., Under the clinical protocol, St. Jude will ref...oton Therapy Institute in Jacksonville, Fla. The p...
Breaking Medicine News(10 mins):Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 2Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2Health News:'No' Votes on Health Care Bill Received $2.3 Million More from Health Insurance Industry 2Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2...ustralians face increasingly large-scale,health ri...onment, ranging from,increases in weather extremes...health., Twelve of Australias top health and medic...ustralians., Released today by Research Australia,...
...research tracks the spread of HIV from Africa to A...s) -- New research into the genetic history of HIV...in Haiti during the middle of the last century, pr... into how HIV evolves and moves from place to plac...
...N, Pa., Oct. 30 ViroPharma Incorporated,(Nasdaq: ...he third quarter,and nine-months ended September 3... Clinical:, -- Patient enrollment began in a Pha...stem cell transplant patients; study enrollment ex...
...es Fiscal Year EPS Outlook for One-time Tax Benefi...e Company (NYSE: PG ) announced net sales growth ... Every reportable segment delivered,mid-single dig... Fabric & Home Care, Baby & Family Care and Groomi...
...CETON, N.J., Oct. 30 Medarex, Inc.,(Nasdaq: MEDX... at the,JPMorgan Small/Mid Cap Conference in Bosto...Time. Medarex,s presentation will be webcast live ...arex.com . About Medarex Medarex is a biopharmac...
...JOSEPH, Mich., Oct. 30 GeneGo, Inc., the leading,...t Elan Pharmaceuticals,Inc. licensed its flagship ...l be available to all scientists in research. Meta... very pleased that Elan chose GeneGo and we have h...
Other Medicine News:Health News:Healthy planet, places and people at risk 2Health News:AIDS Stopped in Haiti Before U.S. 2Health News:AIDS Stopped in Haiti Before U.S. 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 2Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 3Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 4Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 5Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 6Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 7Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 8Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 9Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 10Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 11Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 12Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 13Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 14Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 15Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 16...antly Reduced Signs of Disease Activity as Measure..., 2007 -- Genentech, Inc.,(NYSE: DNA) and Biogen... data from a Phase II clinical study of Rituxan&re...g multiple sclerosis,(RRMS) were presented today a... held in Boston. Rituxan is a therapeutic antibody...
...tzerland, May 2, 2007 – Merck,Serono S.A. (v...,safinamide, a new agent in Phase III development ...ptoms, were presented by Professor,Fabrizio Stocch...,Meeting in Boston, Massachusetts, USA. These data... blind, placebo-controlled,international trial. ,...
Other Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 2Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 3Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 4Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 5VitalWorks Intuition PM Ophthalmology
...ITER Electronic Medical Records (including ExamDRA... record instrument in the industry. Doctors and st...effortless speed and accuracy using our trademarke...ed for typing, we have created the fastest, easies...
Simplex™ P Bone Cement
...1 Gentamicin Bone Cement, a high viscosity antibio...ional market for over a decade, eliminates the inc...e premixed powder helps to prevent inconsistency i...cin Bone Cement provides the same proven character...
Medicine Products: